Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus
2024-515583-32-00Phase 2Authorised
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2024
- Modality
- Cell Therapies
- Countries
- 7
01
Overview
Phase 2, single-arm trial of VX-264 in diabetes mellitus type 1 (T1D), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety and tolerability in Part A, Safety and tolerability in Part B and 1 more. Planned start Sep 2024; status: authorised.
02
Drugs
VX-264
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2024-515583-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515583-32-00.